ReviewBiomedicines2025
The Role of Chemerin in Neutrophil Activation and Diseases of the Lung.
Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disease: A Narrative Review.Cureus · 2026Review
- Decoding chemerin proteolytic processing and isoform signaling across disease contexts.iScience · 2026Review
- Chemerin/ChemerinR1 axis and inflammation-related diseases.Frontiers in molecular biosciences · 2026Review
- Chemerin in Pulmonary Fibrosis: Advances in Mechanistic and Fundamental Research.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemerin is an adipokine with complex biochemistry that undergoes proteolytic modification by components of the inflammatory, coagulation, and fibrinolytic systems, generating both active and inactive products. Chemerin has been found to have both pro- and anti-inflammatory properties, can regulate angiogenesis, and is involved in cancer pathogenesis. Although chemerin is a chemoattractant for macrophages, plasmacytoid dendritic cells, and natural killer cells, it does not induce neutrophil chemotaxis. In contrast, neutrophils appear to act on chemerin structure and localization to regulate the inflammatory response. A role for chemerin in several lung diseases, including airway disease, interstitial lung disease, and cancer, has begun to be explored, but its full role is yet to be fully understood. This review will discuss the role of chemerin in neutrophil activation and will examine what is currently known of the effect of chemerin in diseases of the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.